TY - JOUR
T1 - Survival in small cell lung carcinoma is independent of bcl-2 expression
AU - Maitra, Anirban
AU - Amirkhan, Robin H.
AU - Saboorian, M. Hossein
AU - Frawley, William H.
AU - Ashfaq, Raheela
N1 - Funding Information:
From the Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX: the Department of Academic Computing Services, University of Texas Southwestern Medical Center, Dallas. TX: and the North Texas Veterans Affairs Medical Center, Dallas, TX. Accepted for publication February 5. 1999. Presented in part at the United States and Canadian Academy of Pathology Annual Meeting, Orlando. FL (1997). Supported by a grant from the American Cancer Society. Address correspondence and reprint requests to Raheela Ashfaq, MD. Assistant Professor, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75235-9073. Copyright © 1999 by W.B. Saunders Company 0046-8177/99/3006-0020510.00/0 survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bel-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC. HuM PATnOL 30:712-717. Copyright © 1999 by W.B. Saunders Company Key words-small cell, lung cancer, bcl-2, Survival.
PY - 1999/6
Y1 - 1999/6
N2 - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.
AB - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.
KW - Bcl-2
KW - Lung cancer
KW - Small cell
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0033025610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033025610&partnerID=8YFLogxK
U2 - 10.1016/S0046-8177(99)90099-0
DO - 10.1016/S0046-8177(99)90099-0
M3 - Article
C2 - 10374782
AN - SCOPUS:0033025610
SN - 0046-8177
VL - 30
SP - 712
EP - 717
JO - Human Pathology
JF - Human Pathology
IS - 6
ER -